Frequent but low titre factor VIII inhibitors in haemophilia A patients treated with high purity concentrates

Blood Coagulation and Fibrinolysis

Volumn 10, Issue 3, 1999, Pages 117-120

  Zanon, E ^a   Zerbinati, P ^a   Girolami, B ^a   Bertomoro, A ^a   Girolami, A ^a,b  

^a UNIVERSITY OF PADUA MEDICAL SCHOOL   (Italy)

^b Institute of Medical Semeiotics   (Italy)

Author keywords

Factor VIII inhibitors; Haemophilia

Indexed keywords

BLOOD CLOTTING FACTOR 8 ANTIBODY; BLOOD CLOTTING FACTOR 8 CONCENTRATE; BLOOD CLOTTING FACTOR 8 INHIBITOR; BLOOD CLOTTING FACTOR 8C; HEMOPHIL M; RECOMBINANT BLOOD CLOTTING FACTOR 8; UNCLASSIFIED DRUG;

ANTIBODY PRODUCTION; ANTIBODY TITER; BLOOD TRANSFUSION; CLINICAL ARTICLE; DISEASE SEVERITY; DRUG INDUCED DISEASE; DRUG PURITY; HEMOPHILIA A; HUMAN; PRIORITY JOURNAL; REVIEW;

EID: 0032940024     PISSN: 09575235     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001721-199904000-00001     Document Type: Review

References (14)

1. Aledort L. Inhibitors in haemophilia patients: current status and management. Am J Hematol 1994; 47: 208- 217.
2. Lusher JM, Arkin S, Abildgaard CF, Schwartz RC, and the Kogenate Previously untreated patient study group. Recombinant factor VIII for the treatment of previously untreated patients with haemophilia A. NEJM 1993; 328: 453-459.
3. McMillan CW, Shapiro SS, Whitehurst D, Hoyer LW, Rao AV, Lazerson J. The natural history of Factor VIII:C inhibitors in patients with hemophilia A: a national cooperative study. II. Observations on the initial development of factor VIII:C inhibitors. Blood 1988; 71: 344-348.
4. Ehrenforth S, Kreuz W, Sharrer I, Linde R, Funk M, Gungor T, et al. Incidence of development of factor VIII and factor IX inhibitors in haemophiliacs. Lancet 1992; 339: 594-598.
5. Briet E, Rosendaal FR, Kreuz W, Raisi V, Peerlink K, Vermylen J, et al. High titer inhibitors in severe haemophilia A. A meta-analysis based on eight long- term follow-up studies concerning inhibitors associated with crude or intermediate purity Factor VIII products. Thromb Haemost 1994; 72: 162-164.
6. Bray G, Gomperts ED, Courter S, Gruppo R, Gordon EM, Manco-Johnson M, et al. A multicenter study of recombinant factor VIII (Recombinate): safety, efficacy, and inhibitor risk in previously untreated patients with hemophilia A. Blood 1994; 83: 2428-2435.
7. Addiego J, Kasper C, Abildgaard C, Hilgartner M, Lusher J, Glader B, et al. Frequency of inhibitor development in haemophiliacs treated with low-purity factor VIII. Lancet 1993; 342: 462-464.
8. Kasper CK, Aledort LM, Counts RB. A more uniform measurement of factor VIII inhibitors. Throm Diath Hemorrh 1975; 34: 869.
9. Gill FM. The natural history of factor VIII inhibitors in patients with hemophilia A. Prog Clin Biol Res 1984; 150: 19.
10. Addiego JE, Gomperts E, Liu S-L, Bailey P, Courter SG, Lee ML, et al. Treatment of hemophilia A with a highly purified factor VIII concentrate prepared by anti-FVIIIc immunoaffinity chromatography. Thromb Haemost 1992; 67: 19-27.
11. Schwartz RS, Abilgaard S, Aledort LM and the Recombinant factor VIII Study Group. Human recombinant DNA-derived antihemophilic factor (FVIII) in the treatment of haemophilia A. NEJM 1990; 323: 1800-1895.
12. Rosendaal FR, Nieuwenhuis HK, van den Berg HM, Mauser-Bunschoten EP, van der Meer J, Smit C, et al. A sudden increase in factor VIII inhibitor development in multitransfused hemophilia A patients in the Netherlands. Blood 1992; 81: 2180-2186.
13. Peerlinck K, Arnout J, Gilles JG, Saint-Remy JM, Vermylen J. A higher than expected incidence of factor VIII inhibitors in multitransfused haemophilia A patients treated with and intermediate purity pasteurized factor VIII concentrate. Thromb Haemost 1993; 69: 115-118.
14. Girolami A. The use of clotting factor concentrates in haemorrhagic and thrombotic conditions. Rev Invest Clin 1997; 27: 67-70.